MONTREAL--(BUSINESS WIRE)--Nov. 15, 2005--Ecopia BioSciences Inc. (TSX:EIA) is pleased to announce that it is presenting a scientific poster demonstrating that its lead compound, ECO-4601, is active in vivo against breast and prostate cancer. This poster is presented today in Philadelphia, Pennsylvania at the oncology conference sponsored by the American Association for Cancer Research (AACR), jointly with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC). The data has originally been disclosed by way of a press release dated May 17, 2005. Additional data included in the poster is showing that ECO-4601 needs long-term exposure in order to highlight its potency. “This characteristic is very important in the design of our upcoming Phase I, where patients will be exposed to the compound’s potential benefits over prolonged continuous administration,” commented Pierre Falardeau, President and Chief Executive Officer of the Company. “The safety profile of ECO-4601 is such that long-term exposure is not a problem,” he added. A copy of the poster is available on Ecopia’s website at www.ecopiabio.com under “News - Scientific Publications”.
